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CASE REPORT Open Access
Supraclavicular Subclavian access for
Sapien Transcatheter aortic valve
replacement- a novel approach
Thom G. Dahle*, Nathaniel J. Castro, Brian M. Stegman, Jacob R. Dutcher, John M. Teskey, Wade T. Schmidt,
Daren S. Danielson, Sara J. Dezell, Virginia B. Daniels and Daniel J. Tiede
Abstract
Background: Within the trans-subclavian approach, procedural techniques can vary widely, and reported access
generally refers to an infraclavicular axillary approach. We describe and report the use of a novel supraclavicular true
subclavian approach for transcatheter aortic valve replacement (TAVR) exclusively for implantation of Sapien 3 valves.
Case presentation: We report our first five consecutive patients undergoing TAVR with a Sapien 3 valve using a
standardized subclavian approach at a single center. In-hospital and 30-day complications were reported. The use of
this approach resulted in successful implantation in 100% of patients in a safe manner with 0% mortality, stroke, and
vascular injury during hospitalization and at 30 day follow-up. The in-hospital pacemaker implantation rate was 20%.
The average length of stay was 3 days.
Conclusions: TAVR with Sapien implant can be safely performed with a standardized supraclavicular subclavian
approach in patients with unfavorable femoral access.
Keywords: Supraclavicular, Subclavian, Transcatheter, Aortic, Sapien
Background
Transcatheter aortic valve replacement (TAVR) continues
to expand rapidly as a less invasive option for treatment of
severe aortic stenosis in patients considered high risk or
non-operable for surgical aortic valve replacement. As de-
livery systems have advanced allowing for smaller diameter
sheath sizes, alternative non-femoral access sites including
transapical (TA), trans-subclavian (TS), transcarotid (TC),
transcaval, and direct aortic (DA) have become less com-
mon but still necessary.
Retrospective registry studies have demonstrated similar
procedure outcomes between transfemoral (TF) and TS
access sites and worse outcomes with TA access [1–5].
However, the majority of reported data with TS access has
been performed with CoreValve (Medtronic, Minneapolis,
MN). Data from the UK TAVI registry reported by Frohlich
et al. demonstrated that of 3962 patients who underwent
TAVR from 2007 to 2012, only 188 patients underwent
subclavian access, 99% of which with CoreValve [4]. The
largest study to report TS access with Sapien (Edwards
Lifesciences Inc., Irvine, CA) was by Ciuca et al. from
three Italian centers in which, of the 874 total TAVR pro-
cedures, 60 patients underwent TS access and 24 of which
performed with Sapien XT [5].
Within the TS approach, procedural techniques can vary
widely. In the above subclavian registries, the described sub-
clavian approach was technically transaxillary given the
infraclavicular approach. While infraclavicular axillary access
is well known to cardiothoracic surgeons, supraclavicular
subclavian access is more well known to vascular surgeons.
To our knowledge, we are the first to describe and report
the use of a novel supraclavicular true subclavian approach
exclusively for implantation of Sapien 3 valves.
Case presentation
Beginning in August 2015, we report our first five consecu-
tive patients undergoing TAVR with a Sapien 3 valve using a
standardized subclavian approach at a single center at St.
Cloud Hospital, in St. Cloud, MN. All patients had severe
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symptomatic aortic stenosis as confirmed by echocardiog-
raphy and determined to be high-risk for surgical aortic
valve replacement by two cardiovascular surgeons. Contrast
CT of the chest, abdomen, and pelvis was performed on all
patients to screen the size of the iliofemoral and subclavian
arteries. Patients were found to have iliofemoral or aortic
anatomy that was compromised due to severe tortuosity,
calcification, small caliber, bilateral iliofemoral bypass, or
abdominal aneurysm. All patients underwent pre-procedure
coronary angiography as well as subclavian angiography.
The left subclavian artery was used in all cases given more
favorable delivery angulation relative to the aortic valve and
that the left common carotid usually has a separate takeoff
from arch. Prior to this, we had only performed TAVR from
a supraclavicular subclavian approach on 7 patients with
CoreValve and 5 patients with a Sapien XT valve.
We determined that tables and monitors are best posi-
tioned (as pictured in Fig. 1) off the patients left shoul-
der to reduce flexion and torque on the valve delivery
system. All patients were intubated in a standard fash-
ion. Temporary pacemaker and 6 French (Fr) pigtail
were placed via femoral access. A 4–5 cm incision was
made superior to the clavicle over the lateral head of the
sternocleidomastoid muscle. The lateral head of the
sternocleidomastoid muscle was then transected. Next,
careful dissection was performed until the phrenic nerve
was identified and retracted. Close observation of dia-
phragmatic movement during cautery can be a helpful
clue when dissecting near the phrenic nerve. The anterior
scalene muscle was then transected to expose the
subclavian artery (Fig. 2). Finally, a purse string suture was
made on the anterior surface of the artery around our
chosen access site rather than placement of a conduit due
to reports of conduit evulsion during axillary approach.
Patients were then given IV heparin at 100 units/kg
for a target activated clotting time (ACT) > 250 s. Then,
a direct needle puncture of the artery was performed
followed by placement of a standard 6Fr 11 cm sheath.
We proceeded with crossing the aortic valve through the
6Fr sheath using our standard catheters and straight
wire. Next, an Amplatz Super-stiff 0.035 1-cm tip wire
(Boston Scientific, Marlborough, MA) with manually
shaped distal curve was placed through a 6Fr pigtail
catheter. In our experience, less stiff wires, such as
Amplatz Extra-stiff 0.035 wire (Cook, Bloomington, IN)
or Safari wire (Boston Scientific, Marlborough, MA), do
not provide enough support from a subclavian approach.
With the stiff wire in the ventricle, the 6Fr sheath was
removed and the vessel dilated with the included sheath
dilator followed by insertion of the Edwards eSheath
Fig. 1 Room setup
Dahle et al. Journal of Cardiothoracic Surgery  (2018) 13:16 Page 2 of 5
(Edwards Lifesciences Inc., Irvine, CA) with the logo
towards patient’s feet. This positioned the sheath seam
toward the patient’s head, along the greater curvature of
the sheath, which reduced buckling and kinking of the
sheath. When possible, we upsized to the 16F eSheath,
with 23 mm or 26 mm valve implants, or 18F eSheath,
with 29 mm valve implants, to reduce required push
force. The sheath tip was advanced to mid ascending
aorta to protect aorta during valve insertion. In most
patients this does require a portion of sheath dilator to
cross the aortic valve.
Balloon pre-dilation was optional depending on native
valve characteristics. Next, the valve delivery system was
advanced into proximal ascending aorta and the sheath
withdrawn as needed to expose the valve. The sheath tip
was positioned in the aorta 1–2 cm beyond the
subclavian artery ostium and not into subclavian artery
unless required to provide perfusion to a LIMA graft. In
most patients the nose cone of the unaligned valve did
cross the aortic valve. Valve alignment was performed in
the ascending aorta during which the nose cone would
come back across the AV into the aorta.
The delivery catheter was flexed only as needed for
alignment with the annulus plane. Generally the catheter
did not require any flexion. Positioning and deployment
of the Sapien valve was performed identical to a
standard TF technique. Additional post dilation was
performed only if needed.
Following successful valve deployment, confirmed by
transesophageal echocardiogram, the valve delivery
balloon tip was advanced carefully across the aortic valve
and the super stiff wire withdrawn back into the delivery
catheter to protect the valve leaflets and subclavian
artery from the super-stiff wire. The delivery catheter
was then removed. The sheath was then removed and
hemostasis achieved by tightening the purse-string
sutures. A subclavian angiogram was performed with a
standard Judkins right-4 catheter or pigtail from femoral
access to evaluate for patency and dissection. Anticoagu-
lation was reversed using protamine sulfate. Surgical
closure was performed at the access site (Fig. 3). Place-
ment of a drainage tube was optional and rarely needed.
Post procedure, patients were placed on bed-rest as
per protocol for 6Fr groin access only and monitored for
vascular or nerve complications. On discharge, patients
were instructed to perform no lifting > 10 lbs. with left
arm for 4 weeks, no raising of the left arm greater than
shoulder height for 1 week, and standard post surgical
incision care instructions.
Baseline characteristics of the patients are summarized
in Table 1. During this time period, we did not perform
TAVR from a transapical access as all patients with non-
favorable femoral access were found to have suitable
subclavian anatomy.
In-hospital mortality was 0%. Procedural success defined
as an implanted functioning valve was achieved in all 5
patients (100%). Two patients (40%) required pre-dilation
balloon aortic valvuloplasty. No significant procedural
complications were seen in any patients including major
bleeding or vascular complication. Four patients (80%)
had no or trace perivalvular leak post procedure, 1
patients (20%) had mild perivalvular leak post procedure.
Average total contrast used was 84 ± 32.7 ml. Average
total fluoroscopy time was 14.8 ± 4.1 min.
In-hospital complications included the development of left
bundle branch block (LBBB) in 1 patients (20%) and heart
block in 1 patient (20%) requiring permanent pacemaker
implantation prior to discharge. No patients had minor or
major bleeding, stroke, or vascular complication during their
hospitalization. Average length of stay was 3.0 ± 1.0 days.
At 30 day clinic follow-up mortality was 0%. 30 day com-
plications were seen in one patients who was admitted with
a major gastrointestinal bleed 10 days post procedure.
Fig. 2 Supraclavicular access with exposed subclavian artery
Fig. 3 Supraclavicular access site post surgical closure
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Discussion and conclusions
Currently, the only approved non-femoral access with
the Sapien 3 valve is via TA and DA access, which has
been shown to be associated with worse survival
compared to TF access [6].
In this case series, we demonstrate our first 5 consecu-
tive patients who underwent a novel supraclavicular
subclavian access approach for implantation of Sapien 3
valves. We demonstrated that use of this approach
resulted in successful implantation in 100% of patients
in a safe manner with 0% mortality, stroke, or vascular
injury during hospitalization and at 30 day follow-up.
The in-hospital pacemaker implantation rate was 20% in
this small case series. The average length of stay was
3.0 days. In our case series we did not encounter any
anatomical limitations with this approach.
Although not directly comparable, the Italian registry of
60 patients who underwent TS access (majority implants
with CoreValve) also reported low complication rates with
1% in-hospital mortality, 2% stroke, 3.3% major bleeding,
10% vascular complication, and 27.1% pacemaker implant-
ation (which was driven by valve type with 29.5% patients
receiving CoreValve and 7.1% patients receiving Sapien) [5].
Length of stay was not reported.
Data from the UK TAVI Registry of 188 patients who
underwent subclavian access (99% receiving CoreValve
implant), reported 4.3% in-hospital mortality, 3.0%
stroke, 2.0% Major vascular complication, and 23% pace-
maker implantation [4]. Average length of stay was
7.0 days (5.0–10.0). This study also demonstrated that
in-hospital mortality between the TF group (3.7%) vs SC
group (4.3%) was not significantly different (p = 0.69);
however, mortality in the TA group (9.5%) was signifi-
cantly higher than the TF group (p < 0.0001).
This case series demonstrated the feasibility of performing
TAVR with a Sapien 3 implant using a standardized supra-
clavicular subclavian approach in patients with unfavorable
femoral access. We hypothesize that the advantages of
supraclavicular subclavian access over infraclavicular axillary
access may include reduced tortuosity due to more direct
approach (Fig. 4), easier access in morbidly obese patients,
and familiar access for vascular surgeons. Disadvantage of
this approach compared to infraclavicular axillary access
may include less familiar approach for cardiothoracic
surgeons and less suitable for a percutaneous technique. A
left subclavian approach is favored over the right subclavian
given the more desirable angulation on the left, however a
right sided approach could be used if a dependent LIMA
graft is present and at risk of occlusion by the sheath
(subclavian diameter < 2 mm greater than sheath diameter).
We are experienced at both subclavian and axillary
approaches and find the supraclavicular subclavian approach
very helpful when a percutaneous axillary approach is not
favorable due to smaller axillary artery caliber, significant
additional tortuosity, or presence of a pacemaker over the
axillary access site. However, direct comparison with infra-
clavicular axillary, TF, TA, and DA approaches needs to be
Table 1 Baseline Characteristics of Supraclavicular Subclavian
TAVR patients n = 5
Age, yrs 85 ± 5.0
Female 3 (30.0)
Height, cm 167.9 ± 5.4
Weight, kg 73.3 ± 13.5
STS PROM 4.7 ± 3.2
NYHA functional class III 5 (100.0)
Prior percutaneous coronary intervention 3 (60.0)
Prior coronary artery bypass grafting 1 (20.0)
Prior myocardial infarction 1 (20.0)
Prior stroke 2 (40.0)
Atrial fibrillation 3 (60.0)
Diabetes Mellitus 0 (0.0)
Hypertension 4 (80.0)
History of tobacco use 3 (60.0)
Chronic kidney disease 2 (40.0)
Peripheral arterial disease prohibiting TAVR 5 (100.0)
Chronic lung disease 3 (60.0)
Porcelain aorta 2 (40.0)
Left ventricular ejection fraction, % 62 ± 8.4
Aortic valve area, mm2 0.80 ± 0.17
Aortic valve mean gradient, mmHg 42.4 ± 1.5
Values are mean SD or n (%)
NYHA New York Heart Association, STS PROM Society of Thoracic Surgeons
predicted risk of mortality
Fig. 4 Supraclavicular subclavian vs infraclavicular axillary approach
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studied with Sapien 3. Currently, we are conducting the
ACCESS Study- the first multi-center prospective study
evaluating the implantation of the Sapien 3 valve with the
above described supraclavicular subclavian approach or an
infraclavicular axillary approach compared to TF and TA
approaches.
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